Scoping review protocol maps immune checkpoint inhibitors in definitive radiotherapy for mucosal head and neck cancer
The planned review will examine how immune checkpoint inhibitors fit into the definitive radiotherapy-based treatment pathway for locally advanced mucosal head and neck squamous cell carcinoma. The question is clinically important because concurrent and sequential immunotherapy strategies are being explored across a disease setting where locoregional control, toxicity, and treatment timing all carry immediate bedside consequences. In practice, the review is designed to capture what has already been tested, where those studies sit within the radiotherapy continuum, and how the field has defined eligibility, sequencing, and outcomes.
The protocol is intentionally broad in its search approach and methodologically strict in how it will handle evidence. A comprehensive search will be conducted across four major bibliographic databases, with backward and forward citation searching added to widen capture of relevant studies. No restriction will be placed on publication date or language. This matters in a field where early-phase immunotherapy work may appear in scattered journals, region-specific publications, or older radiotherapy literature that does not fit neatly inside a single modern database query.
The review will follow Joanna Briggs Institute methodology and established guidance for scoping review protocols. A three-step search strategy is planned, and the MEDLINE strategy will undergo peer review before screening begins. Two reviewers will independently select studies, a safeguard that reduces arbitrary exclusions when trial designs are heterogeneous or when terminology shifts across oncology subfields. In a topic like this, where investigators may describe similar treatment concepts with different labels, a disciplined selection process is essential.
Why this question now sits at the center of mucosal head and neck oncology
Definitive radiotherapy remains a core treatment for many patients with locally advanced mucosal head and neck disease, yet the biologic appeal of adding checkpoint blockade is obvious. Radiation can alter antigen presentation, reshape the tumor microenvironment, and potentially prime anti-tumor immunity. Checkpoint inhibitors, in turn, are built to release the brakes on that immune response. The clinical hope is not subtle: improved disease control without taking toxicity beyond what patients can reasonably tolerate during a curative-intent course.
The practical problem is that “immunotherapy plus radiotherapy” is not one uniform intervention. Timing, sequencing, fractionation, and concurrent versus sequential delivery can produce very different biologic and clinical effects. Some strategies may intensify immune activation while others may simply add complexity to already demanding treatment schedules. A scoping review is the right instrument for a field still assembling its vocabulary, because it can chart the territory before anyone tries to quantify effect sizes too early.
One sentence captures the tension in this protocol: the treatment concept is promising, but the evidence base is still being organized.
What the review will include and what it will leave out
Eligibility is restricted to conventionally fractionated definitive radiotherapy-based ICI strategies. Altered-fractionation approaches are excluded, which keeps the review focused on a more homogeneous therapeutic backbone. That choice should help separate the role of checkpoint inhibition from the confounding effect of very different radiotherapy schedules, which can themselves influence tumor response and toxicity.
The protocol also excludes conference abstracts as standalone sources of evidence and will not systematically search unpublished studies or grey literature. That limitation is not trivial in an evolving oncology topic, because some of the earliest signals around novel combinations often appear before full peer-reviewed publication. Still, the tradeoff is methodological clarity: the review is being built around evidence that can be appraised in a stable, citable form.
The preliminary data-charting form will be pilot tested before full extraction begins. So will the eligibility criteria. Both steps are designed to make sure the review captures the same clinical constructs consistently across studies, whether investigators report patient selection, treatment sequencing, toxicity, disease control, or other endpoints in different ways.
A protocol built for mapping, not for treatment claims
This is a scoping review protocol, not a therapeutic recommendation. Its job is to describe the evidence structure surrounding checkpoint inhibitors in the definitive radiotherapy setting, not to declare a standard of care or infer comparative efficacy from scattered studies. That distinction matters because the field likely contains small cohorts, early-phase trials, and methodologically diverse designs that cannot be forced into a single pooled estimate without losing clinical meaning.
The planned review should also help identify where the evidence is thin. For a curative-intent disease process, gaps in sequencing data or toxicity reporting are not academic footnotes; they can shape whether a regimen is adoptable in real clinics. If a strategy appears promising but lacks reproducible treatment timing, dose details, or patient-selection criteria, adoption becomes much harder for radiation oncologists and medical oncologists working at the bedside.
Evidence capture, consistency, and the risk of missing early signals
The search strategy is intentionally expansive across publication date and language, but the protocol is explicit about what it will not systematically capture. Unpublished studies and grey literature will not be comprehensively searched, and conference abstracts will not count as standalone evidence. In a fast-moving immuno-oncology area, that creates a real possibility that some emerging findings remain outside the final evidence map.
Even so, the protocol’s design has clear strengths. Independent screening by two reviewers reduces selection bias. Peer review of the MEDLINE search strategy reduces the chance that key indexing terms are missed. Backward and forward citation searching increases the likelihood of finding relevant work that does not surface through a basic database search alone. Those features matter when the literature may be spread across radiation oncology, head and neck surgery, medical oncology, and immunotherapy journals.
The clinical significance is straightforward. If checkpoint inhibition is going to become a durable part of definitive therapy for locally advanced mucosal head and neck cancer, investigators need to know which combinations have been tested, how they were sequenced with radiation, and which patient populations were represented. A scoping review can answer those foundational questions even when the field is not yet ready for a definitive comparative synthesis.
The protocol therefore functions as a cartographic exercise for an unsettled treatment question. It will not tell clinicians which regimen wins. It will show where the evidence has accumulated, where it thins out, and where future trials still need to define the boundaries of radiotherapy-based immunotherapy in mucosal head and neck cancer.